Gilead Sciences shares fall after company issues disappointing 2026 forecast
Gilead shares fell Tuesday after the firm issued a 2026 outlook below analyst targets. The biotech cited pricing deals and insurance shifts for the low outlook.
Insights:
Gilead Sciences, Inc. issued its 2026 financial forecast today, February 10, 2026, providing a projection that landed at the low end of analyst expectations. The guidance, released at the start of the fiscal year in the US 
US, triggered an immediate market reaction, with the company’s shares falling nearly 6% in after-hours trading. This decline followed the reporting of fourth-quarter results and a 2026 outlook that included lower-than-expected product sales and earnings per share forecasts.
US, triggered an immediate market reaction, with the company’s shares falling nearly 6% in after-hours trading. This decline followed the reporting of fourth-quarter results and a 2026 outlook that included lower-than-expected product sales and earnings per share forecasts.
